Table 4

Antitumor activity: (n = 25) (7/1/03)

Tumor typeDose level at which response occurred (bryostatin μ/m2/24 h)Time to disease progression from cycle 1Prior therapies before enrollmenta
Complete responseDLCL16.524 monthsCHOP (primary refractory)
DLCL4042+ months-continuingCHOP, DHAP, Rituxin, HDC + PBSCT
Partial responseNHL (small lymphocytic)62.527+ months-continuingCHOP
NHL (follicular cell)5015 monthsCVP, rituxin, fludarabine
Mantle cell lymphoma5020 monthsCHOP, Rituxin, DHAP
Stable disease (≥6 months)MM12.56 monthsVAD, MP, VBMCP, high dose cyclophosphamide
NHL (diffuse large cell)12.56 monthsCHOP, DHAP, HD+ PBSCT
MM16.56 monthsMP
NHL (diffuse large cell)3012 monthsCHOP, DHAP
MM3048+ months-continuingVAD, HDC+ PBSCT
  • a DHAP, decadron, cytarabine, cisplatin; MP, melphalan, prednisone; HD + PBSCT, high-dose chemotherapy and peripheral blood stem cell transplantation; VAD, vincristine, doxorubicin, dexamethasone; VBMCP, vincristine, BCNU, cyclophosphamide, melphalan, prednisone; CVP, cyclophosphamide-vincristine-prednisone.